证券代码：605186 证券简称：健麾信息 公告编号：2023-026 上海健麾信息技术股份有限公司 首次公开发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 如有董事对临时公告内容的真实性、准确性和完整性无法保证或存在异议 的，公司应当在公告中作特别提示。 重要内容提示： 本次股票上市类型为首发股份；股票认购方式为网下，上市股数 为 69,368,222 股。 本次股票上市流通总数为 69,368,222 股。 本次股票上市流通日期为 2023 年 12 月 22 日。 一、本次限售股上市类型 2020 年 11 月 27 日，经中国证券监督管理委员会《关于核准上海健麾信 息技术股份有限公司首次公开发行股票的批复》（证监许可[2020]3211 号）核准， 上海健麾信息技术股份有限公司（以下简称"公司"或"健麾信息"）向社会公 众首次公开发行人民币普通股（A 股）34,000,000 股，并于 2020 年 12 月 22 日在上海证券交易所挂牌上市。公司首次公开发行前总股本为 102,000,00 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥64,356,620.87, a decrease of 43.28% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥18,234,704.78, down 41.74% year-on-year[6]. - The net profit excluding non-recurring gains and losses was ¥6,127,927.80, reflecting a significant decline of 78.54% compared to the previous year[6]. - Basic earnings per share for the period were ¥0.13, a decrease of 43.48% from the same quarter last year[6]. - Total operating revenue for the first three quarters of 2023 was ¥241,228,692.12, a decrease of 12.4% compared to ¥275,357,637.72 in the same period of 2022[22]. - Net profit for the first three quarters of 2023 was ¥74,485,546.03, down 13.4% from ¥85,932,346.82 in the previous year[24]. - Earnings per share (EPS) for the first three quarters was ¥0.54, compared to ¥0.63 in the same period last year[24]. - The company reported a profit before tax of ¥83,629,513.60, down from ¥98,880,594.21, a decrease of 15.4%[23]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,300,279,180.23, representing an increase of 8.46% compared to the end of the previous year[6]. - Total assets as of September 30, 2023, reached ¥1,300,279,180.23, up from ¥1,198,844,121.40, indicating an increase of approximately 8.5%[18]. - Non-current assets totaled ¥484,577,931.82, compared to ¥368,877,757.89, marking a significant increase of around 31.3%[18]. - The total liabilities increased to ¥150,033,361.33, compared to ¥115,583,848.53 in the previous year, reflecting a growth of 29.8%[22]. - The total liabilities include accounts payable of ¥35,204,006.22, which increased from ¥24,304,484.12, a rise of approximately 44.8%[18]. - Short-term borrowings amounted to ¥50,000,000.00, indicating the company is leveraging debt[18]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥60,962,902.96 for the year-to-date, a decline of 919.04%[6]. - The net cash flow from operating activities for Q3 2023 was -60,962,902.96, a significant decline compared to 7,443,226.91 in Q3 2022, indicating a negative cash flow trend[28]. - Total cash inflow from financing activities was 50,590,000.00, while cash outflow was 12,055,288.95, resulting in a net cash flow of 38,534,711.05, contrasting with a negative net cash flow of -11,724,045.49 in the same quarter last year[29]. - The total cash and cash equivalents at the end of Q3 2023 stood at 231,996,500.60, down from 387,434,583.17 at the end of Q3 2022, reflecting a decrease of approximately 40% year-over-year[29]. - Cash inflow from investment activities was 24,919,368.46, while cash outflow was 104,610,062.80, leading to a net cash flow of -79,690,694.34, which is a slight increase in negative cash flow compared to -76,612,643.19 in Q3 2022[28]. - Operating cash inflows totaled 221,343,371.29, down from 249,687,999.98 in the previous year, representing a decrease of about 11.3%[28]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,032[14]. - The largest shareholder, Dai Jianwei, holds 57,113,219 shares, representing 42.0% of the total shares[14]. Inventory and Receivables - Accounts receivable increased to ¥363,971,553.84 from ¥332,887,498.88, reflecting a growth of about 9.4%[16]. - The company reported a significant increase in inventory, which rose to ¥89,952,757.14 from ¥74,023,447.28, reflecting a growth of about 21.5%[16]. - Other receivables increased to ¥28,512,117.12 from ¥10,828,485.10, showing a substantial increase of approximately 163.5%[16]. Future Plans - The company attributed the revenue decline to delayed customer purchases and limited business channel expansion, with last year's high base effect due to the post-pandemic recovery in Shanghai[11]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[20]. - The company plans to continue focusing on investment activities despite the negative cash flow, indicating a strategic approach to future growth and market expansion[28]. Audit and Compliance - The company did not conduct an audit for the Q3 financial report, and there were no non-standard opinions from auditors[4].

2023 年半年度报告 公司代码：605186 公司简称：健麾信息 上海健麾信息技术股份有限公司 2023 年半年度报告 1 2023 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人戴建伟、主管会计工作负责人邱泓及会计机构负责人（会计主管人员）祝莺声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 公司已在本报告中描述可能存在的相关风险，敬请投资者予以关注并查阅本报告"第三节管 理层讨论与分析"之"五、其他披露事项"中"（一）可能面对的风险"。敬请投资者注 ...

2023 年第一季度报告 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | | | | 变动幅度(%) | | | 营业收入 | 61,275,234.89 | | 35.03 | | 归属于上市公司股东的净利润 | 9,943,347.23 | | 40.98 | | 归属于上市公司股东的扣除非经常 | 8,916,121.51 | | 2 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2022 is CNY 115,681,544.43, with a total distributable profit of CNY 217,201,772.33 as of December 31, 2022[5]. - The proposed cash dividend is CNY 0.90 per 10 shares (including tax), totaling CNY 12,240,000.00, which represents 10.58% of the net profit attributable to the parent company[5]. - The company's operating revenue for 2022 was CNY 322,359,785.92, a decrease of 34.18% compared to CNY 489,755,358.90 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 115,681,544.43, down 1.65% from CNY 117,618,137.99 in 2021[25]. - The cash flow from operating activities showed a net outflow of CNY -37,261,950.98 in 2022, a decline of 169.22% compared to CNY 53,827,755.74 in 2021[25]. - The basic earnings per share for 2022 was CNY 0.85, a decrease of 1.16% from CNY 0.86 in 2021[27]. - The total assets at the end of 2022 were CNY 1,198,844,121.40, an increase of 6.13% from CNY 1,129,566,326.94 at the end of 2021[26]. - The company reported a decrease in the weighted average return on equity to 12.11% in 2022 from 13.64% in 2021, a reduction of 1.53 percentage points[27]. - The net profit after deducting non-recurring gains and losses was CNY 96,730,991.02, down 10.31% from CNY 107,847,786.04 in 2021[25]. - The total net assets attributable to shareholders increased to CNY 1,004,966,459.25 at the end of 2022, up 11.47% from CNY 901,524,914.82 at the end of 2021[25]. Business Operations and Strategy - The company experienced a significant decline in revenue due to external factors affecting the supply-demand relationship in the industry[27]. - The company secured a CNY 69 million contract for the "Zhongxiang Smart Medical Integrated Project," expanding its "To-G" bulk model business[36]. - The company established joint ventures in various fields, including unmanned medicine dispensing machines and automated logistics, indicating a strategic expansion into new business areas[37]. - A joint venture was signed with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to enhance the company's presence in the Middle East and North Africa markets[38]. - The company focused on improving operational capabilities and management efficiency, implementing strict budget controls and lean production management[39]. - The company is actively pursuing opportunities in the smart pharmaceutical management sector, driven by increasing demands for efficiency and quality in drug dispensing[44]. - The establishment of centralized intravenous medication preparation centers is creating further development space for high-tech automation in the pharmaceutical management field[45]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[55]. - The company’s projects involve a comprehensive approach including hardware and software integration, system design, and ongoing maintenance services[57]. Market Trends and Growth Potential - The global market for automated pharmacy systems is growing, with the average adoption rate in developed countries around 30% as of 2013[43]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, highlighting the trend towards automation in healthcare[43]. - The market for retail pharmacies is expected to grow due to the rise of internet healthcare and automation, with a focus on O2O models[48]. - The company is focusing on expanding its market presence in Hubei and surrounding provinces, leveraging synergies with its existing products[110]. - The market penetration rate of automated pharmacy equipment in China is expected to increase significantly due to rising healthcare investments and policy support, with a projected growth in the industry[111]. - By 2023, the penetration rates for automated pharmacy equipment in various cities are forecasted to rise: Beijing from 4% to 45%, Shenzhen from 6% to 57%, Suzhou from 30% to 65%, and Shanghai from 5% to 48%[112]. Research and Development - The total R&D expenditure amounted to CNY 22,415,836.21, representing 6.95% of operating income[85]. - The company has 70 R&D personnel, accounting for 19.23% of the total workforce[86]. - The company aims to enhance its R&D capabilities and product development, focusing on market-oriented strategies and leveraging technologies like machine vision and deep learning[116]. - A talent development plan will be implemented to strengthen the R&D team and attract experienced professionals to support the company's growth[121]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[3]. - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The internal control system was evaluated as effective, with no significant deficiencies found in financial reporting controls[165]. - The company has established specialized committees under the board, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[147]. - The company has no reported penalties from securities regulatory agencies in the past three years[145]. - The company has maintained a stable leadership structure, with key executives serving since 2017, ensuring continuity in management and strategic direction[137]. Shareholder Relations and Commitments - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with a lock-up extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[180]. - The company has reiterated its commitment to adhere to all relevant laws and regulations regarding shareholding and transfer practices[178]. - The company will ensure compliance with all relevant laws and regulations regarding share repurchase and management[187]. - Major shareholders, including the controlling shareholders, have committed to fulfilling all obligations related to public commitments made during the IPO process[190]. - The company guarantees that the prospectus for the IPO does not contain false records or misleading statements, and it will bear legal responsibility for its accuracy[193].

Group 1: Company Performance and Recovery - The company resumed full operations on June 1, 2022, after being approved as a second batch of companies for resumption in Shanghai [3] - The overall business performance remained stable despite the impact of the COVID-19 pandemic [3] - The company has implemented refined management strategies to adapt to the pandemic situation [4] Group 2: Market Position and Client Base - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, with more than half of the top 100 hospitals in China as clients [3] - The company focuses on the pharmaceutical intelligent management sector and has a strong market presence in economically developed coastal regions, particularly in first and second-tier cities [4] Group 3: Future Strategy and Business Development - In 2022, the company aims to enhance product development and market expansion while optimizing production and management efficiency [4] - The company plans to explore the "to-G" market and increase its market share in the retail pharmaceutical sector [4] - The company has a strategic layout for the retail market and aims to penetrate lower-tier medical service institutions [4]

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第三季度报告 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 113,472,020.66 | -14.92 | 275,357,637.72 | -3.4 | | 归属于上市公司股东 ...

重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年半年度报告 公司代码：605186 公司简称：健麾信息 上海健麾信息技术股份有限公司 2022 年半年度报告 1 / 166 2022 年半年度报告 八、 是否存在违反规定决策程序对外提供担保的情况？ 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人 戴建伟、主管会计工作负责人邱泓及会计机构负责人（会计主管人员）祝莺声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中描述可能存在的相关风险， ...

2021 年年度报告 公司代码：605186 公司简称：健麾信息 上海健麾信息技术股份有限公司 2021 年年度报告 1 / 199 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人戴建伟、主管会计工作负责人邱泓及会计机构负责人（会计主管人员）祝莺声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本利润分配预案尚需提交公司股东大会审议。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 根据公司实际经营状况，经公司第二届董事会第十一次会议决议，公司2021年年度拟以实施 权益分派股权登记日登记的总股本为基数分 ...

2022 年第一季度报告 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 1 / 13 2022 年第一季度报告 | 基本每股收益（元/股） | | 0.05 | 0 | | --- | --- | --- | --- | | 稀释每股收益（元/股） | | 0.05 | 0 | | 加权平均净资产收益率（%） | | 0.78 | 0 | | | 本报告期末 | 上年度末 | 本报告期末比 上年度末增减 变动幅度(%) | | 总资产 | 1,064,942,116.69 | 1,129,5 ...